Iscalimab (CFZ533) in Patients with Sjogren's Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study

被引：0
|
作者：
Fisher, Benjamin A. [1 ]
Mariette, Xavier [2 ]
Papas, Athena S. [3 ]
Grader-Beck, Thomas [4 ]
Bootsma, Hendrika [5 ]
Ng, Wan-Fai [6 ]
Van Daele, Paul [7 ]
Finzel, Stephanie [8 ]
Elgueta, Sergio [9 ]
Hermann, Josef [10 ]
McCoy, Sara [11 ]
Bookman, Arthur [12 ]
Sopala, Monika [13 ]
Luo, Wen-Lin [14 ]
Scheurer, Cornelia [13 ]
Hueber, Wolfgang [13 ]
机构：
[1] Univ Birmingham, Birmingham, W Midlands, England
[2] Univ Paris Saclay, Le Kremlin Bicetre, France
[3] Tufts Sch Dent Med, Div Oral Med, Boston, MA USA
[4] Johns Hopkins Sch Med, Div Rheumatol, Baltimore, MD USA
[5] Univ Med Ctr Groningen, Dept Rheumatol, Groningen, Netherlands
[6] Newcastle Tyne Hosp NHS Fdn Trust, NIHR Newcastle Clin Res Facil, Newcastle Upon Tyne, Tyne & Wear, England
[7] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands
[8] Univ Freiburg, Univ Med Ctr Freiburg, Dept Rheumatol & Clin Immunol, Freiburg, Germany
[9] Clin Res Chile SpA, Biomed Res Ctr, Valdivia, Chile
[10] Med Univ Graz, Dept Internal Med, Div Rheumatol & Immunol, Graz, Austria
[11] Univ Wisconsin, Sch Med & Publ Hlth, Middleton, WI USA
[12] Toronto Western Hosp, Toronto, ON, Canada
[13] Novartis Pharma AG, Basel, Switzerland
[14] Novartis Pharmaceut, E Hanover, NJ USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1634
引用
收藏
页码：3242 / 3244
页数：3
相关论文
共 50 条
  • [41] Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study
    Dicpinigaitis, Peter H.
    Morice, Alyn A.
    Smith, Jaclyn R.
    Sher, Mandel
    Vaezi, Michael
    Guilleminault, Laurent
    Niimi, Akio
    Gude, Kerstin
    Krahn, Ulrike
    Saarinen, Riitta
    Pires, Philippe Vieira
    Wosnitza, Melanie
    McGarvey, Lorcan
    PAGANINI Investigators
    LUNG, 2023, 201 (03) : 255 - 266
  • [42] EFFICACY AND SAFETY OF ATACICEPT IN PATIENTS WITH HIGH DISEASE ACTIVITY IN A 24-WEEK, RANDOMIZED, PLACEBO-CONTROLLED, PHASE IIB STUDY (ADDRESS II)
    Merrill, J. T.
    Wallace, D. J.
    Kao, A.
    Mateo, C. Vazquez
    Fraser, P. A.
    Chang, P.
    Isenberg, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 856 - 856
  • [43] A phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD)
    Wollenberg, Andreas
    Howell, Michael D.
    Guttman-Yassky, Emma
    Silverberg, Jonathan I.
    Birrell, Claire
    Kell, Chris
    Dawson, Michelle
    van der Merwe, Rene
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB20 - AB20
  • [44] Late Breaking Abstract - Efficacy and safety of eliapixant in refractory chronic cough: Results of the PAGANINI 12-week, randomized, placebo-controlled Phase 2b study
    McGarvey, Lorcan
    Morice, Alyn H.
    Smith, Jaclyn
    Sher, Mandel
    Vaezi, Michael
    Guilleminault, Laurent
    Niimi, Akio
    Roth, Katrin
    Saarinen, Riitta
    Pires, Philippe Vieira
    Wosnitza, Melanie
    Dicpinigaitis, Peter
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [45] A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis
    Gupta, AK
    Leonardi, C
    Stoltz, RR
    Pierce, PF
    Conetta, B
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2005, 19 (04) : 437 - 443
  • [46] The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial
    Emery, P
    Fleischmann, R
    Filipowicz-Sosnowska, A
    Schechtman, J
    Szczepanski, L
    Kavanaugh, A
    Racewicz, AJ
    Van Vollenhoven, RF
    Li, NF
    Agarwal, S
    Hessey, EW
    Shaw, TM
    ARTHRITIS AND RHEUMATISM, 2006, 54 (05): : 1390 - 1400
  • [47] A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause
    Fraser, Graeme L.
    Lederman, Samuel
    Waldbaum, Arthur
    Kroll, Robin
    Santoro, Nanette
    Lee, Misun
    Skillern, Laurence
    Ramael, Steven
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2020, 27 (04): : 382 - 392
  • [48] Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a 24-week randomized, placebo-controlled trial (ASSERT)
    van der Heijde, D
    Dijkmans, B
    Geusens, P
    Sieper, J
    DeWoody, K
    Williamson, R
    Braun, J
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 403 - 403
  • [49] A 12-WEEK, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 2B STUDY OF SAFETY, TOLERABILITY AND EFFICACY OF AR882 IN GOUT PATIENTS
    Wei, J. C. C.
    Fleischmann, R. M.
    Morris, S.
    Polvent, E.
    Shen, Z.
    Roche, A. Clouser
    Hingorani, V.
    Yan, S.
    Yeh, L. T.
    Keenan, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 192 - 192
  • [50] Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
    Papp, K. A.
    Langley, R. G.
    Sigurgeirsson, B.
    Abe, M.
    Baker, D. R.
    Konno, P.
    Haemmerle, S.
    Thurston, H. J.
    Papavassilis, C.
    Richards, H. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (02) : 412 - 421
12345